Skip to main content

Iomeprol use while Breastfeeding

Medically reviewed by Last updated on Jul 7, 2022.

Iomeprol Levels and Effects while Breastfeeding

Summary of Use during Lactation

Iomeprol is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Labeling for the drug in the United Kingdom and guidelines developed by several professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a iodine-containing contrast medium such as iomeprol.[1-4]

Drug Levels

Maternal Levels. Four mothers who were 1 week to 14 months postpartum received iohexol by rapid intravenous injection. Three received a dose of 50 mL (37.8 grams; 17.5 grams of iodine) and one received 60 mL (45.3 grams; 21 grams of iodine). Milk samples of 10 mL were collected 9 times over the 48 hours after the injection. The average iohexol milk concentration over the first 24 hours was 24.6 mg/L in the 3 women 1 week to 4 months postpartum and 130.5 mg/L in the one woman who was 14 months postpartum and weaning her infant. The authors calculated that the average amount of iohexol received by the first 3 infants over the first 24 hours would be 3.7 mg/kg or 0.5% of the weight-adjusted maternal dosage.[5]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

A preterm infant, born at 31 weeks 4 days, was noted at 17 days of age to have a markedly elevated thyrotropin (TSH) value of 87.6 mUI/L (normal range: 0.27 to 4.20 mUI/L). TSH had been normal at birth. Thyroglobulin was also elevated at 811 ng/mL (normal range: 3.5 to 77 ng/mL), but free T4 was normal. The infant had been breastfed (extent not stated) from birth, but also received partial parenteral nutrition until day 10 of life. The infant’s mother had received iomeprol in a dose of 350 mg/kg of iodine at day 4 postpartum and discontinued breastfeeding for 24 hours after the dose. The mother had a history of subclinical hypothyroidism and was treated with levothyroxine.[6] The infant’s transient hypothyroidism, indicated by elevations in TSH and thyroglobulin, was probably caused by the iodine in milk from the contrast medium.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider



American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2018;Version 10.3:99. https://www​​/media/ACR/Files/Clinical-Resources​/Contrast_Media.pdf. Accessed Oct 7, 2019.
Webb JA, Thomsen HS, Morcos SK, et al. The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol. 2005;15:1234–40. [PubMed: 15609057]
Chen MM, Coakley FV, Kaimal A, et al. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112:333–40. [PubMed: 18669732]
Copel J, El-Sayed Y, Heine RP, et al. Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. Obstet Gynecol. 2017;130:e210–e6. [PubMed: 28937575]
Nielsen ST, Matheson I, Rasmussen JN, et al. Excretion of iohexol and metrizoate in human breast milk. Acta Radiol. 1987;28:523–6. [PubMed: 2960342]
Themelin C, Pierron C, Calafat JF, et al. Transient neonatal hypothyroidism secondary to postnatal maternal exposure to contrast medium. BMJ Case Rep. 2019;12:e230854. [PMC free article: PMC6803084] [PubMed: 31619400]

Substance Identification

Substance Name


CAS Registry Number


Drug Class

Breast Feeding


Contrast Media

Diagnostic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

More about iomeprol

Professional resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.